Effect of heart failure on the outcome of COVID-19 — A meta analysis and systematic review

Yonas, Emir; Alwi, Idrus; Pranata, Raymond; Huang, Ian; Lim, Michael Anthonius; Gutierrez, Eddy Jose; Yamin, Muhammad; Siswanto, Bambang Budi; Virani, Salim S.

doi:10.1016/j.ajem.2020.07.009

Cited by 117 publications

(118 citation statements)

References 56 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…It is a well-validated, simple, easy-to-apply index to evaluate patients’ prognosis and survival. During the current pandemic, the severity and mortality of COVID-19 are often predicted by age, gender, and the presence of comorbidities, such as diabetes, cardiovascular, cerebrovascular, and respiratory diseases [ [34] , [35] , [36] , [37] , [38] , [39] , [40] ]. Advanced age and multiple comorbidities are independent risk factors of mortality for patients with COVID-19 [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis

Kuswardhani

Henrina

Pranata

et al. 2020

Diabetes & Metabolic Syndrome: Clinical Research & Revi

Self Cite

225

161

View full text Add to dashboard Cite

Background and aims The ongoing COVID-19 pandemic is disproportionately affecting patients with comorbidities. Therefore, thorough comorbidities assessment can help establish risk stratification of patients with COVID-19, upon hospital admission. Charlson Comorbidity Index (CCI) is a validated, simple, and readily applicable method of estimating the risk of death from comorbid disease and has been widely used as a predictor of long-term prognosis and survival. Methods We performed a systematic review and meta-analysis of CCI score and a composite of poor outcomes through several databases. Results Compared to a CCI score of 0, a CCI score of 1–2 and CCI score of ≥3 was prognostically associated with mortality and associated with a composite of poor outcomes. Per point increase of CCI score also increased mortality risk by 16%. Moreover, a higher mean CCI score also significantly associated with mortality and disease severity. Conclusion CCI score should be utilized for risk stratifications of hospitalized COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis

Kuswardhani

Henrina

Pranata

et al. 2020

Diabetes & Metabolic Syndrome: Clinical Research & Revi

Self Cite

225

161

View full text Add to dashboard Cite

show abstract

“…Obesity and diabetes mellitus (DM) are independent, significant risk factors for mortality in coronavirus disease 2019 (COVID-19) [ 5 , 16 ]. The presence of excessive body mass index (BMI) and type 2 DM in patients with severe COVID-19 is quite prevalent among other comorbidities, including advanced age, hypertension, and heart, lung, kidney, liver, and cerebrovascular diseases [ [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] ]. In addition, physical inactivity or sedentariness commonly observed in these subjects contributed to impaired immune function and increased morbidity and mortality in COVID-19, regardless of the presence of insulin resistance [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis

Lukito

Pranata

Henrina

et al. 2020

Diabetes & Metabolic Syndrome: Clinical Research & Revi

Self Cite

View full text Add to dashboard Cite

“…1 While COVID-19 is easily contracted, only a minority of patients with particular comorbidities will develop severe COVID-19 with features of hyper-inflammation and complications, including acute respiratory distress syndrome (ARDS), multi-organ failure (MOF), and death. [2][3][4][5][6] Hypothetically, the fate of this relentless pandemic might finally be decided by the discovery of either a vaccine or definite treatment for COVID -19. Ever since preliminary evidence was released, showing that anticoagulant administration could reduce mortality of patients with severe COVID-19, 7 the issues of thrombosis and coagulopathy have gained special attention in the pathogenesis and treatment of COVID-19. The persistence of a high incidence of venous thromboembolism (VTE) even in patients with COVID-19 treated with a standard thromboprophylaxis dose of anticoagulants raises the question of whether the administration of therapeutic-dose anticoagulants may improve the prognosis of patients with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review

Wijaya

Andhika

Huang

2020

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a systematic review in order to explore the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19. A systematic search was carried out using the electronic databases of PubMed, EuropePMC, and the Cochrane Central Database, using specific keywords. All articles that fulfilled the inclusion criteria were included in the qualitative analysis. There were 8 observational studies included in the final qualitative analysis. Quality assessment using the Newcastle-Ottawa Scale (NOS) showed a mean score of 7.5 ± 1.06, indicating moderate to high quality of the studies. Three retrospective cohort studies reported a reduction in the mortality rate, while 6 other studies showed no mortality benefits among patients with COVID-19 treated with therapeutic-dose anticoagulation. There was a slight tendency toward a reduction in the mortality rate among mechanically-ventilated patients with COVID-19 receiving therapeutic-dose anticoagulation. Bleeding events and thrombotic complications among patients receiving therapeutic-dose anticoagulation were reported in 3 studies. Although it is too soon to draw any conclusions, this systematic review draws attention to current evidence regarding the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19.

show abstract

Effect of heart failure on the outcome of COVID-19 — A meta analysis and systematic review

Cited by 117 publications

References 56 publications

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis

The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review

Contact Info

Product

Resources

About